Related Experiment Video

Updated: Jun 19, 2026

Exercise Test for Evaluation of the Functional Efficacy of the Pig Cardiovascular System
02:47

Exercise Test for Evaluation of the Functional Efficacy of the Pig Cardiovascular System

Published on: May 12, 2023

Drug trials in pediatric heart failure: hype or improved clinical science?

Robert E Shaddy1

  • 1University of Utah School of Medicine, Department of Pediatrics, 100 North Medical Drive, Salt Lake City, UT 84113, USA. robert.shaddy@ihc.com

Future Cardiology
|October 7, 2009
PubMed

Insights

Evidence for pediatric heart failure therapies is scarce due to challenges in drug trial design. This perspective outlines these obstacles and proposes solutions for conducting pediatric heart failure drug trials.

Area of Science:

  • Pediatric Cardiology
  • Clinical Pharmacology
  • Translational Medicine

Background:

  • Limited evidence exists to guide pediatric heart failure (PHF) therapy.
  • Significant challenges hinder the development of a robust evidence base for PHF treatments.

Purpose of the Study:

  • To define the obstacles in conducting well-designed drug trials for pediatric heart failure.
  • To propose potential structures for developing and implementing pediatric heart failure drug trials.

Main Methods:

  • This is a perspective piece, not an empirical study.
  • It involves a critical review of existing challenges in pediatric clinical trial design.
  • It synthesizes expert opinion and proposes innovative trial frameworks.

Main Results:

  • Identifies key challenges including patient recruitment, ethical considerations, and outcome measures in PHF trials.
  • Proposes adaptable trial designs and collaborative approaches to overcome these hurdles.
  • Highlights the need for innovative methodologies tailored to the pediatric population.

Conclusions:

  • Addressing the identified obstacles is crucial for advancing pediatric heart failure treatment.
  • Implementing proposed trial structures can facilitate the generation of essential evidence.
  • Improved drug trial methodologies are vital for optimizing therapeutic strategies in pediatric heart failure.

More Related Videos

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine10:05

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine

Published on: July 7, 2016

Related Concept Videos

Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...